Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674122 | 0.80 | AOC3 (0.36) | DRD2SLC6A4MAP3K5CYP11B1CYP11B2 | |
| SCHEMBL31162523 | 0.76 | RPS6KA5 (0.36) | DRD2SLC6A4MAP3K5CYP11B1CYP11B2 | |
| SCHEMBL23937774 | 0.70 | ELANE (0.34) | DRD2SLC6A4CYP11B1CYP11B2 | |
| SCHEMBL20673865 | 0.65 | CHEK2 (0.35) | CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL20631767 | 0.64 | MEN1 (0.35) | — | |
| SCHEMBL23937881 | 0.64 | PARP1 (0.37) | DRD2SLC6A4MAP3K5 | |
| SCHEMBL21959623 | 0.64 | PDE10A (0.32) | DRD2SLC6A4CYP11B1CYP11B2 | |
| SCHEMBL20674571 | 0.64 | MAP3K5 (0.37) | DRD2SLC6A4MAP3K5OPRM1OPRD1 | |
| SCHEMBL1514912 | 0.60 | CYP1A2 (0.42) | — | |
| SCHEMBL30838793 | 0.60 | CYP1A2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | DRD2 4236/4885SLC6A4 2138/4885MAP3K5 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.